QQQ   424.69 (-0.27%)
AAPL   168.00 (+0.00%)
MSFT   409.16 (-0.65%)
META   505.10 (+2.21%)
GOOGL   155.38 (-0.06%)
AMZN   180.92 (-0.20%)
TSLA   149.85 (-3.60%)
NVDA   844.80 (+0.53%)
AMD   154.92 (+0.58%)
NIO   3.91 (+0.00%)
BABA   69.13 (+0.45%)
T   16.13 (+0.06%)
F   12.06 (+0.17%)
MU   116.70 (+0.32%)
GE   157.60 (+1.24%)
CGC   6.53 (+0.62%)
DIS   112.99 (+0.04%)
AMC   2.80 (-6.04%)
PFE   25.38 (-0.16%)
PYPL   63.07 (-0.30%)
XOM   118.65 (+0.02%)
QQQ   424.69 (-0.27%)
AAPL   168.00 (+0.00%)
MSFT   409.16 (-0.65%)
META   505.10 (+2.21%)
GOOGL   155.38 (-0.06%)
AMZN   180.92 (-0.20%)
TSLA   149.85 (-3.60%)
NVDA   844.80 (+0.53%)
AMD   154.92 (+0.58%)
NIO   3.91 (+0.00%)
BABA   69.13 (+0.45%)
T   16.13 (+0.06%)
F   12.06 (+0.17%)
MU   116.70 (+0.32%)
GE   157.60 (+1.24%)
CGC   6.53 (+0.62%)
DIS   112.99 (+0.04%)
AMC   2.80 (-6.04%)
PFE   25.38 (-0.16%)
PYPL   63.07 (-0.30%)
XOM   118.65 (+0.02%)
QQQ   424.69 (-0.27%)
AAPL   168.00 (+0.00%)
MSFT   409.16 (-0.65%)
META   505.10 (+2.21%)
GOOGL   155.38 (-0.06%)
AMZN   180.92 (-0.20%)
TSLA   149.85 (-3.60%)
NVDA   844.80 (+0.53%)
AMD   154.92 (+0.58%)
NIO   3.91 (+0.00%)
BABA   69.13 (+0.45%)
T   16.13 (+0.06%)
F   12.06 (+0.17%)
MU   116.70 (+0.32%)
GE   157.60 (+1.24%)
CGC   6.53 (+0.62%)
DIS   112.99 (+0.04%)
AMC   2.80 (-6.04%)
PFE   25.38 (-0.16%)
PYPL   63.07 (-0.30%)
XOM   118.65 (+0.02%)
QQQ   424.69 (-0.27%)
AAPL   168.00 (+0.00%)
MSFT   409.16 (-0.65%)
META   505.10 (+2.21%)
GOOGL   155.38 (-0.06%)
AMZN   180.92 (-0.20%)
TSLA   149.85 (-3.60%)
NVDA   844.80 (+0.53%)
AMD   154.92 (+0.58%)
NIO   3.91 (+0.00%)
BABA   69.13 (+0.45%)
T   16.13 (+0.06%)
F   12.06 (+0.17%)
MU   116.70 (+0.32%)
GE   157.60 (+1.24%)
CGC   6.53 (+0.62%)
DIS   112.99 (+0.04%)
AMC   2.80 (-6.04%)
PFE   25.38 (-0.16%)
PYPL   63.07 (-0.30%)
XOM   118.65 (+0.02%)

AstraZeneca (AZN) Competitors

$68.41
-0.12 (-0.18%)
(As of 09:52 AM ET)

AZN vs. NVS, ABT, PFE, ABBV, SNY, MRK, VRTX, REGN, BMY, and GSK

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novartis (NVS), Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Sanofi (SNY), Merck & Co., Inc. (MRK), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), and GSK (GSK). These companies are all part of the "pharmaceutical preparations" industry.

AstraZeneca vs.

Novartis (NYSE:NVS) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.

Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.6%. AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.8%. Novartis pays out 33.8% of its earnings in the form of a dividend. AstraZeneca pays out 100.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis has raised its dividend for 4 consecutive years and AstraZeneca has raised its dividend for 1 consecutive years.

Novartis received 474 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.49% of users gave Novartis an outperform vote while only 57.61% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
NovartisOutperform Votes
527
61.49%
Underperform Votes
330
38.51%
AstraZenecaOutperform Votes
53
57.61%
Underperform Votes
39
42.39%

Novartis has higher earnings, but lower revenue than AstraZeneca. Novartis is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$45.44B4.34$14.85B$7.1812.97
AstraZeneca$45.81B4.64$5.96B$1.9235.69

Novartis has a net margin of 29.83% compared to Novartis' net margin of 13.00%. Novartis' return on equity of 30.19% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis29.83% 29.90% 12.97%
AstraZeneca 13.00%30.19%11.57%

13.1% of Novartis shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AstraZeneca had 5 more articles in the media than Novartis. MarketBeat recorded 24 mentions for AstraZeneca and 19 mentions for Novartis. Novartis' average media sentiment score of 0.68 beat AstraZeneca's score of 0.32 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
8 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
AstraZeneca
10 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive

Novartis has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Novartis presently has a consensus target price of $104.33, indicating a potential upside of 12.08%. AstraZeneca has a consensus target price of $80.00, indicating a potential upside of 16.74%. Given Novartis' stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

AstraZeneca beats Novartis on 11 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$212.47B$6.23B$4.75B$7.41B
Dividend Yield2.80%3.12%2.90%3.97%
P/E Ratio35.6917.80270.6119.02
Price / Sales4.64214.622,413.9787.70
Price / Cash12.7429.8747.5435.34
Price / Book5.435.494.634.20
Net Income$5.96B$99.27M$102.17M$212.41M
7 Day Performance-1.32%-7.30%-4.80%-4.60%
1 Month Performance4.07%-5.83%-4.36%-3.16%
1 Year Performance-8.65%-3.39%10.22%4.59%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVS
Novartis
2.4164 of 5 stars
$93.19
-1.3%
$104.33
+12.0%
-5.0%$197.53B$45.44B12.9876,057Upcoming Earnings
ABT
Abbott Laboratories
4.9943 of 5 stars
$109.20
+0.3%
$122.14
+11.9%
+1.3%$189.48B$40.11B33.50114,000Earnings Report
Short Interest ↓
News Coverage
PFE
Pfizer
4.9926 of 5 stars
$25.69
-0.8%
$36.88
+43.5%
-38.3%$145.47B$58.50B71.3688,000Analyst Report
ABBV
AbbVie
4.9075 of 5 stars
$162.54
+0.5%
$177.43
+9.2%
+1.9%$287.80B$54.32B59.5450,000Short Interest ↓
Analyst Revision
SNY
Sanofi
3.2004 of 5 stars
$45.80
-1.0%
$55.00
+20.1%
-17.5%$115.86B$46.61B19.4186,088Upcoming Earnings
Analyst Revision
News Coverage
MRK
Merck & Co., Inc.
4.7527 of 5 stars
$125.06
-0.9%
$131.25
+4.9%
+9.0%$316.78B$60.12B893.2972,000Upcoming Earnings
Positive News
VRTX
Vertex Pharmaceuticals
4.192 of 5 stars
$394.17
-0.8%
$424.62
+7.7%
+19.9%$101.88B$9.87B28.385,400Analyst Report
Analyst Revision
REGN
Regeneron Pharmaceuticals
3.5746 of 5 stars
$894.14
-0.5%
$970.57
+8.5%
+9.9%$98.14B$13.12B25.7313,450Analyst Report
BMY
Bristol-Myers Squibb
4.9344 of 5 stars
$48.27
-0.5%
$61.12
+26.6%
-32.3%$97.83B$45.01B12.5134,100Upcoming Earnings
Analyst Downgrade
Short Interest ↓
Analyst Revision
GSK
GSK
2.6197 of 5 stars
$39.95
-1.4%
N/A+5.9%$82.78B$37.71B13.2770,200News Coverage

Related Companies and Tools

This page (NASDAQ:AZN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners